FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Keyword: BRCA1, Categories Cancer Treatment
Update : New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23)
Este artículo está disponible en español.
Read More
Update : New first-line treatment option for metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in certain genes.
The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)
Este artículo está disponible en español.
Read More
Update : New drug combination for early treatment of some metastatic prostate cancer
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2
The FDA approved Lynparza (olaparib) for use earlier in treatment of metastatic castration-resistant prostate cancer (mCRPC) when added to abiraterone and prednisone for people with a BRCA mutation found through genetic or tumor testing. Lynparza combined with hormone therapy may now be used as a first-line or later treatment. (Posted 9/11/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Promising early results for treating metastatic prostate cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with metastatic castration-resistant prostate cancer (mCRPC)
The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)
Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage.
Este artículo está disponible en español.
Read More
Update : Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations
Most relevant for: People with a BRCA1 or PALB2 mutation undergoing prophylactic bilateral mastectomy
A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Male breast cancer: Patient and surgeon experiences
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: Men with breast cancer
By surveying male breast cancer patients and the surgeons who treat them, researchers gained insight into the experiences of both groups, shedding light on an important issue for men with breast cancer. (Posted 12/22/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Study : More is not better: PARP dose can be safely reduced for people with ovarian cancer
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People taking a PARP inhibitor for ovarian cancer maintenance therapy
Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)
Este artículo está disponible en español.
Read More
Update : PARP inhibitors withdrawn as third-line or later treatment for recurrent ovarian cancer
Most relevant for: people with recurrent ovarian cancer who have received 3 or more prior lines of treatment and who have an inherited or tumor mutation in BRCA1 or BRCA2 or whose tumor is HRD positive
Survival data from a clinical trial signaled that PARP inhibitors may not work as well as chemotherapy for patients with recurrent ovarian cancer who have received three or more lines of treatment. As a result, FDA approvals have been withdrawn for PARP inhibitors in this setting. This does not affect PARP inhibitor approvals for use as maintenance therapy for ovarian cancer. (Posted 10/4/22)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.
This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors. (posted 9/6/2022)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Screening for pancreatic cancer detects early-stage disease and improves survival
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People at increased risk for pancreatic cancer because of family history or an inherited mutation.
A research study has shown that screening for pancreatic cancer in people with an inherited mutation or family history was able to detect early-stage pancreatic cancers and improve survival. These results will likely change pancreatic cancer screening guidelines for high-risk individuals (Posted 8/30/22)
Este artículo está disponible en español.
Read More